DeepCyte ApS
Private limited companyCVR 45398293København NActive
DeepCyte ApS is a private limited company, based in København N, active in research and experimental development on natural sciences and engineering, founded in 2025. Equity was negative at the end of 2025 (−DKK 2.2m). The company is new and has been registered for 1 years. The latest net result (2025) was a loss of DKK 2.3m.
Key figures · financial year 2025
What has changed
calculated from recorded figures and datesEmployees
- 1 more employees than a year earlier: 2 (07/2026) against 1 (07/2025).
Management and owners, last 24 months
- New in management: Carl Joseph Gabriel Evertsz (chair of the board, 12/02/2025), Theodore Alexandrov (director, 12/02/2025) and Theodore Alexandrov (board member, 12/02/2025).
- New owners registered: DeepCyte Inc. (12/02/2025).
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2025–2025 · amounts in DKK thousand| 2025 | Change | |
|---|---|---|
| Revenue | 111 | – |
| Gross profit | −1,392 | – |
| Operating profit (EBIT) | −2,253 | – |
| Profit before tax | −2,283 | – |
| Net profit | −2,283 | – |
| Total assets | 334 | – |
| Equity | −2,243 | – |
| Liabilities | 2,578 | – |
| Cash and cash equivalents | 236 | – |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresNegative equity
Equity was −DKK 2.2m at the end of 2025.
How is this calculated?
Equity in the latest annual report is below zero.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
1 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 12/02/2025 – 31/12/2025 | 27/03/2026 | The company | PDF not statedXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
431 companies in the databaseComparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.
Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 68,979of 69,742 Better than 1% | No. 68,383of 69,964 Better than 2% |
| Same industry and fewer than 20 employees329 companies in the comparison | No. 259of 323 Better than 20% | No. 274of 329 Better than 17% |
| Companies that are founded within the last five years16,675 companies in the comparison | No. 16,369of 16,627 Better than 2% | No. 16,277of 16,674 Better than 2% |
| All companies of type ApS66,508 companies in the comparison | No. 65,774of 66,379 Better than 1% | No. 64,923of 66,505 Better than 2% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Research and experimental development on natural sciences and engineering- DeepCyte ApS−DKK 1.4m
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- DeepCyte ApS−DKK 2.3m
- Carlsberg A/SDKK 7bn
- Zealand Pharma A/SDKK 6.5bn
- DeepCyte ApS−DKK 2.2m
- Carlsberg A/SDKK 30.7bn
- Zealand Pharma A/SDKK 14.8bn
- DeepCyte ApS2
- Carlsberg A/S107
- Zealand Pharma A/S569
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership Register- DeepCyte Inc.100%
Management
3 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Theodore Alexandrov | Director | 12/02/2025 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Carl Joseph Gabriel Evertsz | Chair of the board | 12/02/2025 |
| Theodore Alexandrov | Board member | 12/02/2025 |
- Founders
- DeepCyte Inc.
Signing rule: Virksomheden tegnes af en direktør eller af den samlede bestyrelse i forening.
Address and production units
1 active production unitsOle Maaløes Vej 3
2200 København N
København Municipality · Postcode 2200
Other companies at the address (8)
- BII Holdings A/SOther financial service activities n.e.c.
- Skape Bio ApSResearch and experimental development on natural sciences and engineering
- Agrobiomics ApSResearch and experimental development on natural sciences and engineering
- Tetrakit Technologies ApSResearch and experimental development on natural sciences and engineering
- BioColor ApSResearch and experimental development on natural sciences and engineering
| Production unit | Address | Employees | P number |
|---|---|---|---|
| DeepCyte ApS | Ole Maaløes Vej 3, 2200 København N | 2 | 1031073312 |
Purpose
Virksomhedens formål er at udvikle og sælge innovative produkter, tjenester og intellektuelle ejendomsrettigheder fokuseret på at karakterisere celler, væv og andre prøver, som kan anvendes på en lang række områder, herunder sundhedspleje, bioteknologi og farmakologi, med det formål at forbedre patientresultater og fremme videnskabelige fremskridt samt enhver i forbindelse hermed stående virksomhed.
The purpose is quoted from the register in Danish.
Changes year by year
6 registered events20261 changeaccounts 1
- AccountsAnnual report for 2025 published
20255 changesfounded 1 · management 3 · ownership 1
- FoundedRegistered as DeepCyte ApS
- ManagementCarl Joseph Gabriel Evertsz appointed chair of the board
- ManagementTheodore Alexandrov appointed director
- ManagementTheodore Alexandrov appointed board member
- OwnershipDeepCyte Inc. registered as owner (100%)
Related companies
Same industry in København
- Genmab A/S676 employees
- 3shape A/S518 employees
- Carlsberg A/S107 employees
- IQVIA RDS Denmark A/S100 employees
- Nuevolution A/S100 employees
- Sunshine Enterprise Holding A/S73 employees
Largest in the industry
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Gubra A/SDKK 2.6bn
- Vestas Wind Systems A/SDKK 2.5bn
- Bang & Olufsen A/SDKK 1.4bn
- 3shape A/SDKK 1.3bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.